

Masahito Nakano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4011798/publications.pdf>

Version: 2024-02-01

33
papers

693
citations

516710

16
h-index

580821

25
g-index

35
all docs

35
docs citations

35
times ranked

1005
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound. <i>Cancer Reports</i> , 2022, 5, e1471.	1.4	7
2	Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study. <i>Cancer Reports</i> , 2022, 5, e1539.	1.4	3
3	Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. <i>Scientific Reports</i> , 2022, 12, 1517.	3.3	10
4	Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1483.	2.4	0
5	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. <i>Cancers</i> , 2022, 14, 2295.	3.7	3
6	Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. <i>Hepatology Communications</i> , 2022, 6, 2594-2604.	4.3	3
7	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. <i>Cancers</i> , 2021, 13, 160.	3.7	38
8	Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 14, 79.	1.0	8
9	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 646.	3.7	19
10	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 987.	2.4	7
11	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. <i>Cancers</i> , 2021, 13, 2786.	3.7	44
12	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. <i>Oncology</i> , 2021, 99, 756-765.	1.9	4
13	First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. <i>Cancer Medicine</i> , 2021, 10, 8530-8541.	2.8	12
14	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Cancers</i> , 2021, 13, 5282.	3.7	11
15	Association between contrast enhancement on contrast-enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 8.	1.0	2
16	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. <i>Cancers</i> , 2020, 12, 1867.	3.7	56
17	Primary Treatment with Molecularly-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. <i>Hepatology Communications</i> , 2020, 4, 1218-1228.	4.3	21
18	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. <i>Nutrients</i> , 2020, 12, 1076.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. <i>Cancers</i> , 2020, 12, 1010.	3.7	42
20	High serum interleukin-34 level is a predictor of poor prognosis in patients with nonviral hepatocellular carcinoma. <i>Hepatology Research</i> , 2019, 49, 1046-1053.	3.4	21
21	Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. <i>Cancer Medicine</i> , 2019, 8, 2646-2653.	2.8	27
22	Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision tree analysis after propensity score matching. <i>Hepatology Research</i> , 2019, 49, 919-928.	3.4	42
23	Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. <i>Hepatology International</i> , 2019, 13, 293-301.	4.2	38
24	Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. <i>Oncology</i> , 2019, 96, 192-199.	1.9	4
25	Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. <i>Oncology</i> , 2019, 96, 79-86.	1.9	9
26	Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extrahepatic spread: A prospective cohort study. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1013-1020.	1.0	27
27	Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 243-250.	2.3	21
28	Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. <i>Oncotarget</i> , 2016, 7, 64400-64409.	1.8	3
29	Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. <i>Cancer Medicine</i> , 2015, 4, 1836-1843.	2.8	54
30	Serum albumin level is a notable profiling factor for non-B, non-C hepatitis virus-related hepatocellular carcinoma: A data-mining analysis. <i>Hepatology Research</i> , 2014, 44, 837-845.	3.4	26
31	Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. <i>Molecular and Clinical Oncology</i> , 2014, 2, 393-398.	1.0	64
32	Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2013, 84, 108-114.	1.9	31
33	Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan. <i>Hepatology Research</i> , 2010, 40, 989-996.	3.4	9